Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 7/20 | 0.62 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13071050 | 0.99 | NOTUM (0.61) | NOTUMPDE3BPDE3AKDRHRH3 | |
| SCHEMBL1769796 | 0.99 | NOTUM (0.61) | NOTUMPDE3BPDE3AKDRHRH3 | |
| SCHEMBL13071350 | 0.90 | NOTUM (0.54) | NOTUMPDE3BPDE3AKDR | |
| SCHEMBL12649035 | 0.90 | NOTUM (0.51) | NOTUMPDE3BPDE3AKDRPDE4A | |
| SCHEMBL26699650 | 0.90 | NOTUM (0.51) | NOTUMPDE3BPDE3AKDRPDE4A | |
| SCHEMBL12648793 | 0.89 | NOTUM (0.65) | NOTUMPDE3BPDE3AKDRHRH3 | |
| SCHEMBL1769904 | 0.89 | PDE3B (0.55) | NOTUMPDE3BPDE3A | |
| SCHEMBL1769918 | 0.88 | PDE3B (0.59) | NOTUMPDE3BPDE3AKDRHRH3 | |
| SCHEMBL13070902 | 0.86 | PDE3B (0.60) | NOTUMPDE3BPDE3AKDRHRH3 | |
| SCHEMBL25698377 | 0.85 | NOTUM (0.47) | NOTUMPDE3BPDE3AKDRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212146-B2 | Substituted pyridazinones for the treatment of tumors | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-15 | — | — | US | disclosed |
| US-9212146-B2 | Substituted pyridazinones for the treatment of tumors | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2015-12-15 | — | — | US | disclosed |
| US-20130281426-A1 | PYRIDAZINONES, THE PREPARATION METHOD AND THE USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 2013-10-24 | — | — | US | disclosed |
| US-20130281426-A1 | PYRIDAZINONES, THE PREPARATION METHOD AND THE USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES | 2013-10-24 | — | — | US | disclosed |
| US-8501731-B2 | Derivatives of 6[3-(trifluoromethyl)phenyl]pyridazin-3(2H)-one having antitumor activity | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2013-08-06 | — | — | US | disclosed |
| EP-2253625-B1 | PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF | SHANGHAI INST MATERIA MEDICA (CN) | 2013-03-13 | — | — | EP | disclosed |
| EP-2253625-A1 | PYRIDAZINONES, THE PREPARATION AND THE USE THEREOF | Shanghai Institute Materia Medica, Chinese Academy Of Sciences (CN) | 2010-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281426-A1 | PYRIDAZINONES, THE PREPARATION METHOD AND THE USE THEREOF | CYP3A5, PDXK, HCCS | NOTUM 3416/4885PDE3B 3489/4885PDE3A 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.